Also, in SK-LU1 xenografted mice, the application of the αEGFR-mAB-P/KRAS-siRNA/P nanostructures reduced tumour sizes and weights by about 50% when compared with the control-treated groups (Fig. 6C, E, G). The gene discussed is KRAS; the disease is neoplasm.